Search
What are you looking for?
Start main content

Press Releases

Press Releases

https://www.med.cuhk.edu.hk/press-releases/antiviral-therapy-can-prevent-liver-cancer-recurrencecuhk-represents-hk-to-draw-up-asian-pacific-treatment-guideline-for-chronic-hepatitis-b
https://www.med.cuhk.edu.hk/press-releases/antiviral-therapy-can-prevent-liver-cancer-recurrencecuhk-represents-hk-to-draw-up-asian-pacific-treatment-guideline-for-chronic-hepatitis-b

Antiviral Therapy Can Prevent Liver Cancer Recurrence CUHK Represents HK to Draw Up Asian Pacific Treatment Guideline for Chronic Hepatitis B

Hepatocellular carcinoma (HCC) is one of the top cancer killers in Hong Kong. In 2009, it ranked fourth in cancer incidence (1,832 cases) and third in cancer mortality (1,488 cases). In Hong Kong, over 80% of HCC is caused by hepatitis B virus infection. In all current clinical practice guidelines, antiviral treatment is recommended for patients who suffer liver cirrhosis or active hepatitis. Although surgical resection and loco-regional therapy can be applied to small HCC, about 70% of the patients suffer HCC recurrence within five years after the surgical resection. It is still unclear whether antiviral therapy can prevent HCC recurrence. The Center for Liver Health at The Chinese University of Hong Kong (CUHK) has conducted a meta-analysis to sum up the evidence in the literature on the role of antiviral therapy to prevent HCC recurrence after surgical resection and loco-regional therapy, and is representing Hong Kong in drawing up the latest guideline for chronic hepatitis B management. 

 

From left: Prof. Henry Lik Yuen CHAN, Professor, Department of Medicine and Therapeutics and Director of Center for Liver Health; and Prof. Grace Lai Hung WONG, Associate Professor, Department of Medicine and Therapeutics at CUHK present their recent meta-analysis, which reveals that antiviral treatment was associated with risk reduction for Hepatocellular carcinoma (HCC) recurrence in chronic hepatitis B patients who have HCC resected or treated by loco-regional therapy

From left: Prof. Henry Lik Yuen CHAN, Professor, Department of Medicine and Therapeutics and Director of Center for Liver Health; and Prof. Grace Lai Hung WONG, Associate Professor, Department of Medicine and Therapeutics at CUHK present their recent meta-analysis, which reveals that antiviral treatment was associated with risk reduction for Hepatocellular carcinoma (HCC) recurrence in chronic hepatitis B patients who have HCC resected or treated by loco-regional therapy.

High level of hepatitis B virus replication, as reflected by high HBV DNA level, is one of the key factors leading to the development of HCC. Among patients who undergo surgical resection of HCC, those who have higher HBV DNA level tend to have a higher risk of HCC recurrence. There were many studies conducted in the past few years trying to find out whether antiviral therapy can prevent HCC recurrence, but the sample sizes were usually small and failed to provide accurate data analysis.


Up to March 2010, The Center for Liver Health at CUHK studied nine literature reporting HCC recurrence in chronic hepatitis B patients. 551 patients were studied, of which 204 had antiviral treatment and 347 were untreated controls. The analysis reveals that antiviral treatment was associated with over 40% risk reduction for HCC recurrence as compared with the untreated controls. Furthermore, antiviral treatment was associated with more than 85% reduction in risk of liver failure and more than 70% risk reduction in death after HCC treatment.

Based on the strong evidence of this analysis, CUHK is representing Hong Kong in drawing up the chronic hepatitis B management consensus guideline of the Asian Pacific Association for the Study of the Liver. The guideline recommends chronic hepatitis B patients who have HCC resected or treated by loco-regional therapy to receive antiviral therapy if they have high level of HBV DNA (>2000 IU/ml).

More Press Releases

CUHK-HCC Score Accurately Predicts Risk of Liver Cancer in Chronic Hepatitis B Patients Receiving Antiviral Therapy

CUHK-HCC Score Accurately Predicts Risk of Liver Cancer in Chronic Hepatitis B Patients Receiving Antiviral Therapy

Research
CUHK Study Reveals Patients with Recovery of Hepatitis B Still at Risk of Liver Cancer

CUHK Study Reveals Patients with Recovery of Hepatitis B Still at Risk of Liver Cancer

Research
CUHK and French Researchers Pioneer the Use of Non-Invasive Imaging Technology – New XL Probe to Assess Liver Disease in Obese Patients

CUHK and French Researchers Pioneer the Use of Non-Invasive Imaging Technology – New XL Probe to Assess Liver Disease in Obese Patients

Research
CUHK Discovers the Use of Hepatitis B Surface Antigen Level as a New Marker for Disease Control in Chronic Hepatitis B Patients

CUHK Discovers the Use of Hepatitis B Surface Antigen Level as a New Marker for Disease Control in Chronic Hepatitis B Patients

Research
CUHK study reveals risk of liver-related complications but not liver cancer decreases over time in patients who have recovered from hepatitis B, regular cancer surveillance is recommended

CUHK study reveals risk of liver-related complications but not liver cancer decreases over time in patients who have recovered from hepatitis B, regular cancer surveillance is recommended

Research
CU Medicine Study Shows Liver Injury is Common and Prognostic in COVID-19 Patients

CU Medicine Study Shows Liver Injury is Common and Prognostic in COVID-19 Patients

Research
CUHK Survey: About 90% Hepatitis C Patients Unaware of Infection and Majority Refuses Treatment

CUHK Survey: About 90% Hepatitis C Patients Unaware of Infection and Majority Refuses Treatment

Research
CUHK Develops Lifestyle Modification Program for Fatty Liver Patients 60% Patients Recovered Without Use of Drugs

CUHK Develops Lifestyle Modification Program for Fatty Liver Patients 60% Patients Recovered Without Use of Drugs

Health Campaign
CUHK Pioneers the Use of a New Non-Invasive Imaging Technology to Measure Fatty Liver - a problem affecting 27% of the adult population in HK

CUHK Pioneers the Use of a New Non-Invasive Imaging Technology to Measure Fatty Liver - a problem affecting 27% of the adult population in HK

Research
CUHK Estimates One Million Hong Kong People are Suffering from Fatty Liver Disease

CUHK Estimates One Million Hong Kong People are Suffering from Fatty Liver Disease

Research
CUHK Discovers High Prevalence of Colorectal Polyps among Fatty Liver Patients

CUHK Discovers High Prevalence of Colorectal Polyps among Fatty Liver Patients

Research
CU Medicine uncovers the keys for liver cancer adaptation to immunotherapy Pioneering new combination therapy in a Phase II clinical trial

CU Medicine uncovers the keys for liver cancer adaptation to immunotherapy Pioneering new combination therapy in a Phase II clinical trial

Research
CU Medicine proves oral antivirals for COVID-19 can lower the risk of hospitalisation and  inpatient progression in older patients living in nursing homes

CU Medicine proves oral antivirals for COVID-19 can lower the risk of hospitalisation and inpatient progression in older patients living in nursing homes

Research
CUHK Uncovers a New Strategy to Turn “Cold” Liver Tumour “Hot” Leading to an Effective and Durable Combined Immunotherapy

CUHK Uncovers a New Strategy to Turn “Cold” Liver Tumour “Hot” Leading to an Effective and Durable Combined Immunotherapy

Research
CUHK Discovers an Essential Oncogene in Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma

CUHK Discovers an Essential Oncogene in Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma

Research
CUHK Study Proves Ablative Chemoembolization Doubles the Progression-Free Survival for Liver Cancer Patients

CUHK Study Proves Ablative Chemoembolization Doubles the Progression-Free Survival for Liver Cancer Patients

Research
CUHK Reveals Non-Alcoholic Fatty Liver Disease Afflicts Even the Non-Obese

CUHK Reveals Non-Alcoholic Fatty Liver Disease Afflicts Even the Non-Obese

Research
CUHK Discovers Fatty Liver Causing Severe Liver Fibrosis or Cirrhosis in 1 Out of 5 Diabetic Patients

CUHK Discovers Fatty Liver Causing Severe Liver Fibrosis or Cirrhosis in 1 Out of 5 Diabetic Patients

Research
CUHK Latest Research Reveals over 100,000 New Non-alcoholic Fatty Liver Cases in Hong Kong Annually

CUHK Latest Research Reveals over 100,000 New Non-alcoholic Fatty Liver Cases in Hong Kong Annually

Research
CUHK Reveals Hepatitis B Prevalence Among Pregnant Women Remains High Despite More Than 25 Years of Universal Hepatitis B Vaccination

CUHK Reveals Hepatitis B Prevalence Among Pregnant Women Remains High Despite More Than 25 Years of Universal Hepatitis B Vaccination

Research
CUHK Reveals Effectiveness of TEA for Treating Liver Cancer with a 70% Chance of Completely Destroying Tumor

CUHK Reveals Effectiveness of TEA for Treating Liver Cancer with a 70% Chance of Completely Destroying Tumor

Research
CUHK Assessed and Treated Over 300 Young Ketamine Abusers with Urinary Tract Dysfunction Latest Research Reveals Effectiveness of Integrated Anti-inflammatory Therapy

CUHK Assessed and Treated Over 300 Young Ketamine Abusers with Urinary Tract Dysfunction Latest Research Reveals Effectiveness of Integrated Anti-inflammatory Therapy

Research
CUHK Received Four Ministry of Education Higher Education Outstanding Scientific Research Output Awards The Highest Share among Hong Kong Institutions

CUHK Received Four Ministry of Education Higher Education Outstanding Scientific Research Output Awards The Highest Share among Hong Kong Institutions

Awards and honors
Why is Liver Cancer More Prevalent in Men than in Women? CUHK Discovers a Sex Hormone-controlled Gene that Promotes Liver Cancer

Why is Liver Cancer More Prevalent in Men than in Women? CUHK Discovers a Sex Hormone-controlled Gene that Promotes Liver Cancer

Research
Three CUHK Scholars Named Croucher Senior Research Fellow 2011-12

Three CUHK Scholars Named Croucher Senior Research Fellow 2011-12

Awards and honors

Our Expert List

Many experts under the Faculty of Medicine are available for media interview.
Please click here for the expert list or contact us.